reptides › focus › humanin

humanin

a 24-amino-acid peptide your mitochondria encode. cytoprotective and metabolic biology in cells and rodents. zero interventional human trials.

tier C · focus · 24 aa mitochondrial-derived

verdict

the first mitochondrial-derived peptide ever described. real, replicated cytoprotective and metabolic biology in cell and rodent models. no completed interventional human trial.

if you're asking whether humanin works in humans yet — there is no completed interventional human trial of humanin. the human data that exists is observational: circulating humanin is measurable in blood and cerebrospinal fluid, tends to decline with age, and tracks with markers in conditions like mitochondrial disease and metabolic dysfunction. that is biomarker work on the body's own peptide, not a study of giving humanin to people and measuring an outcome. the therapeutic case is built on cell and rodent models.

if you're asking about the cytoprotective / neuroprotective biology — in cells and rodents the effect is real and replicated. humanin was first identified in a surviving region of an Alzheimer's brain and characterized as anti-apoptotic, protecting neurons from amyloid-beta toxicity in culture. the proposed mechanism runs through STAT3 signaling and modulation of IGFBP3 and the pro-apoptotic protein Bax. follow-up rodent work extended the signal to metabolic and stress-protection endpoints. the biology is interesting; it has not been tested as a treatment in people.

if you came in via the longevity / mitokine framing — humanin is encoded in mitochondrial DNA and behaves as a stress-responsive signaling peptide, which is genuinely novel biology. circulating levels falling with age is an association, not a demonstrated lever on aging. this site does not frame humanin as a lifespan or anti-aging therapy, because no human outcome data supports that. honest version: a well-characterized mitochondrial-derived peptide with strong preclinical cytoprotective signal and no interventional human evidence.

based on published evidence. not medical advice.

why C-tier

C-tier because the mechanism is plausible and unusually well-characterized for an unapproved compound, but the human evidence is thin: observational endogenous-biomarker work only, with zero completed interventional trials. Not D-tier because the preclinical biology is genuinely real and replicated, not failed or contradicted, and the mitochondrial-derived-peptide field is serious academic science. Not B-tier because B requires a stronger evidence trajectory toward humans, and humanin has no registered interventional clinical program the way MOTS-c now does. Humanin sits in C as 'real, novel biology in cells and rodents, no human treatment data yet.'

the core tension

humanin is encoded inside mitochondrial DNA, not the nuclear genome, and it was the first peptide of its kind ever described. the cytoprotective and anti-apoptotic biology is real and replicated in cells and rodents, with a well-mapped STAT3/IGFBP3 mechanism. the entire gap is the same one that defines the mitochondrial-derived peptide field: no completed interventional human trial exists. the human evidence is observational, circulating humanin declines with age and associates with disease markers, which is biomarker movement rather than therapeutic outcome.

what it is

humanin is a 24-amino-acid peptide encoded within the MT-RNR2 region of mitochondrial DNA, the gene for the mitochondrial 16S ribosomal RNA. it was the first member of the mitochondrial-derived peptide (MDP) class to be described, identified in 2001 from a region of brain tissue that survived in Alzheimer's disease. it behaves as a stress-responsive signaling peptide, secreted from cells and detectable in circulation, where it appears to act on cytoprotective and metabolic pathways.

what it does

in cell and rodent models humanin is cytoprotective and anti-apoptotic. it protects cultured neurons from amyloid-beta toxicity, and the proposed mechanism runs through STAT3 signaling, modulation of IGFBP3, and inhibition of the pro-apoptotic protein Bax. rodent work has extended the signal into metabolic regulation (insulin sensitivity, glucose handling) and broader stress protection. circulating humanin is measurable in humans and tends to decline with age.

origin

discovered in 2001 by Yuichi Hashimoto and colleagues, identified in the occipital lobe of an Alzheimer's patient, a region relatively spared from neurodegeneration. later characterized further by Pinchas Cohen's lab at USC, the same group central to the mitochondrial-derived peptide field. encoded inside the mitochondrial genome rather than the nucleus, which made it a founding example of the MDP concept.

why researchers are interested

the biology is novel and the preclinical record is consistent. humanin was the first peptide shown to be encoded inside mitochondrial DNA and to act as a signaling molecule, which reframed mitochondria as more than power plants. the cytoprotective and anti-apoptotic mechanism is well-characterized for an unapproved compound, and the age-declining circulating-level finding is a clean, repeatedly observed human biomarker.

does it work

in cells and rodents, the cytoprotective effect is real and replicated. the human evidence is observational only: humanin is measurable in blood and cerebrospinal fluid, declines with age, and associates with markers in mitochondrial and metabolic disease. that is endogenous-biomarker work, not a study of administering humanin to people. there is no completed interventional human trial. humanin is not FDA-approved and has no approved administration protocol. the therapeutic case is mechanism plus animal data plus an age-associated biomarker, which is exactly why it sits in C: plausible, well-studied at the bench, unproven as a treatment.

claims vs the data

  • encoded inside mitochondrial DNA as a signaling peptide — supported — Humanin is encoded within the MT-RNR2 (16S rRNA) region of mitochondrial DNA and was the first peptide of this mitochondrial-derived class to be described (Hashimoto et al., 2001). The MDP concept is now an established research area.
  • cytoprotective and anti-apoptotic in preclinical models — supported — Replicated in cell and rodent models. Humanin protects neurons from amyloid-beta toxicity in culture and inhibits apoptosis via STAT3 signaling and modulation of Bax/IGFBP3. Mechanism is well-characterized for an unapproved compound.
  • regulates metabolic endpoints like insulin sensitivity — partially true — Rodent studies report effects on insulin sensitivity and glucose handling. The metabolic signal is real in animals; it has not been tested by administering humanin to humans.
  • circulating humanin declines with age in humans — supported — Multiple human observational studies report that measurable circulating humanin is higher in younger people and declines with age. This is endogenous-biomarker data, not the result of administering humanin.
  • treats Alzheimer's or neurodegenerative disease in humans — contradicted — Humanin was discovered in surviving Alzheimer's brain tissue and is neuroprotective in cell models, but no completed interventional human trial has tested it as a treatment for any neurodegenerative disease. The therapeutic claim outruns the evidence.
  • extends lifespan or reverses aging in humans — contradicted — There is no human outcome evidence for a lifespan or anti-aging effect. The age-declining circulating-level finding is an association, not a demonstrated lever on aging, and no interventional human trial exists.

key facts

  • molecular formula: C119H204N34O32S2
  • molecular weight: ~2687 Da
  • amino acids: 24
  • half-life: short in plasma (minutes); analogs were engineered for greater stability, downstream signaling effects persist longer
  • type: mitochondrial-derived peptide (MDP)
  • CAS: 330936-69-1
  • 2001 year of discovery (first MDP described)
  • 24 amino acids; encoded in mtDNA (MT-RNR2)
  • 0 completed interventional human trials
  • declines circulating humanin falls with age (observational)

frequently asked questions

What is humanin?

Humanin is a 24-amino-acid mitochondrial-derived peptide encoded within the MT-RNR2 (16S rRNA) region of mitochondrial DNA. It was the first mitochondrial-derived peptide ever described, identified in 2001 from a surviving region of an Alzheimer's brain.

What does humanin do?

In preclinical models humanin is cytoprotective and anti-apoptotic, protecting cells from stress and amyloid-beta toxicity, with proposed signaling through STAT3 and IGFBP3 and effects on metabolic and neuroprotective endpoints. In humans, circulating humanin is measurable and tends to decline with age, but this is biomarker data, not the result of administering humanin.

How is humanin typically administered?

There is no FDA-approved administration protocol for humanin. No completed interventional human trial has established a route, dose, or schedule. Any conventions circulating online are not clinically validated.

What are the side effects of humanin?

The safety profile in humans has not been characterized, because there is no completed interventional human trial. Preclinical work has not flagged a consistent toxicity signal, but the absence of human exposure and outcome data means the safety profile remains unknown.

Is humanin FDA approved?

No. Humanin has no FDA approval. It is an investigational research peptide studied in cell and animal models and in human observational (endogenous-biomarker) work, with no completed interventional clinical trial and no drug-approval status.

How much does humanin cost?

There is no clinical retail price. On the research-chemical market it tends to price higher than simpler peptides, reflecting the synthesis complexity of a 24-amino-acid sequence.

related peptides

  • mots-c — companion mitochondrial-derived peptide, metabolic focus, also preclinical-dominant
  • ss-31 — FDA-approved mitochondrial peptide, different mechanism vs humanin's preclinical-only status
  • epithalon — another aging-research peptide running on thin human evidence

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.